InvestorsHub Logo
Followers 12
Posts 224
Boards Moderated 0
Alias Born 05/11/2015

Re: None

Monday, 06/19/2017 11:15:04 AM

Monday, June 19, 2017 11:15:04 AM

Post# of 2543
Looks like Integumen is making some progress. This is from their page on the London Stock exchange:
LINK: http://www.londonstockexchange.com/exchange/news/alliance-news/detail/1497861781782666400.htmlurl

Integumen Gets Labskin Orders From La Prairie, Merck, Galderma
[ 19 Jun 2017 09:43 ]

LONDON (Alliance News) - Integumen PLC on Monday said it has received orders from three companies in the skincare, dermatology and pharmaceutical space - La Prairie, Merck & Co Inc and Galderma SA - for its Labskin product.


Integumen is a personal healthcare company which develops technology and products for the human integumentary system, including skin.


Labskin is a three-dimensional human skin equivalent model that resembles the discrete biological layers found in human skin and can be used by skincare and dermatology developers as an alternative to testing on animals.


Integumen said Swiss-based premium beauty brand La Prairie - which is owned by German personal care company Beiersdorf AG - has placed orders to conduct efficacy trials using Labskin for certain materials in its range of products.


Meanwhile, US pharmaceutical developer Merck has signed an evaluation order with Integumen for the Labskin model, while Galderma - a dermatology subsidiary of Swiss consumer goods giant Nestle - has ordered Labskin for testing of materials and formulations in its headquarters in Lausanne, Switzerland.


"We are delighted to receive these orders from such reputable blue chip clients. With an ever-increasing focus on the human microbiome, Labskin's advantage of being able to host bacteria in a similar environment to that of human skin is proving to be an attractive option for companies focussed on R&D in skincare," Chief Executive Declan Service said in a statement.


"While relatively small in revenue terms, these orders not only demonstrate our ability to commercialise our products and technologies which is what we promised to do at IPO, but also our ability to build relationships with established companies," he added.


Shares in Integumen were untraded on Monday, last quoted at 3.00 pence.


By Karolina Kaminska; karolinakaminska@alliancenews.com; @KarolinaAllNews


Copyright 2017 Alliance News Limited. All Rights Reserved.


Please don't rely on my posts as advice. They are strictly my opinion on the subject.........Cyndlu

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.